Trial Profile
A phase III multicenter, double-blind, parallel-group, placebo controlled study to measure the effect of riluzole 50 mg b.i.d. over a period of three years on the progression of Huntington's disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jan 2007
Price :
$35
*
At a glance
- Drugs Riluzole (Primary)
- Indications Huntington's disease
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 12 Jan 2007 Status change
- 14 Sep 2006 New trial record.